Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
Rhea-AI Summary
Alzamend Neuro (NASDAQ: ALZN) reported preliminary pharmacodynamic MRS data from a healthy-subject study (N=6) at Massachusetts General Hospital on April 7, 2026. After two weeks of blood-bioequivalent AL001 versus lithium carbonate, AL001 trended toward myo-inositol reduction in 17 of 18 brain regions and showed minimal glutamate effects in 10 of 18 regions. Results are qualitative and require statistical confirmation in larger, adequately powered patient studies now underway.
Positive
- Myo-inositol reduced in 17 of 18 brain regions with AL001
- Preserved glutamate homeostasis in 10 of 18 brain regions after AL001
- Two-week blood-bioequivalent comparison versus lithium carbonate in humans
Negative
- Small sample size of N=6 limits statistical confidence
- Preliminary qualitative findings require further statistical confirmation
- Lithium carbonate showed large effects across all brain regions
News Market Reaction – ALZN
On the day this news was published, ALZN declined 2.47%, reflecting a moderate negative market reaction. Argus tracked a peak move of +5.0% during that session. Argus tracked a trough of -11.8% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $101K from the company's valuation, bringing the market cap to $3.99M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, ALZN was down 4.98% while momentum scanner peers CYCN and IBO showed downside moves of 5.78% and 4.52% without same-day news, pointing to stock-specific factors rather than a coordinated sector move.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Phase II topline data | Positive | -22.3% | Reported positive Phase II topline data showing brain bioequivalence and higher uptake. |
| Nov 19 | Phase II completion | Positive | -5.3% | Announced completion of clinical portion of Phase II healthy-subject study for AL001. |
| May 29 | Phase II dosing start | Positive | +63.9% | Began dosing first patient in Phase II AL001 brain-absorption study at MGH. |
| May 19 | First patient enrolled | Positive | +5.9% | Enrolled first patient in Phase II trial comparing AL001 vs lithium carbonate. |
| May 13 | Phase II trial initiated | Positive | -18.8% | Initiated first Phase II AL001 study evaluating brain and blood pharmacokinetics. |
Clinical-trial headlines for AL001 have produced mixed reactions: several large upside moves but also notable selloffs on positive updates, indicating inconsistent trading response to similar catalysts.
Over the past year, Alzamend has steadily advanced its AL001 “Lithium in Brain” program at Massachusetts General Hospital. Starting with Phase II initiation in May 2025 and early patient enrollment, the company progressed to completion of the clinical portion by Nov 19, 2025, then reported positive topline brain-delivery and bioequivalence data on Mar 26, 2026. Price reactions to these clinical milestones have varied, with both sharp rallies and declines, so today’s pharmacodynamic MRS update fits into a pattern of significant but inconsistently rewarded trial news.
Historical Comparison
Clinical-trial news for AL001 has triggered volatile but mixed reactions, with an average move of 4.66%. Today’s MRS pharmacodynamic readout extends that same Phase II program at MGH within this established pattern.
Clinical updates show a clear progression: initiation and first enrollment in May 2025, dosing later that month, completion of the healthy-subject Phase II portion by Nov 2025, and positive topline brain-delivery data in Mar 2026, now followed by detailed pharmacodynamic MRS findings.
Market Pulse Summary
This announcement adds qualitative pharmacodynamic MRS data to AL001’s Phase II program, suggesting distinct brain effects versus lithium carbonate, broader myo-inositol reduction across 17 of 18 regions, and more stable glutamate in 10 of 18 regions. Historically, similar clinical-trial news produced mixed price reactions despite progress. Investors may watch for larger, statistically powered studies, capital-raising activity from the $3.0 million ATM, and Nasdaq compliance efforts when assessing future developments.
Key Terms
magnetic resonance spectroscopy medical
pharmacodynamic medical
myo-inositol medical
glutamate medical
glutamate homeostasis medical
therapeutic drug monitoring medical
ionic cocrystal technical
systemic exposure medical
AI-generated analysis. Not financial advice.
- Potentially Distinct Brain Profile: Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than lithium carbonate
- Expected Trends for Myo-Inositol Reduction: Both AL001 and lithium carbonate showed a trend toward reducing myo-inositol, potentially supporting the hypothesis that AL001 retains lithium's core mechanism of action
- Potentially Preserved Glutamate Balance: Lithium carbonate showed large effects across all brain regions whereas AL001 showed minimal glutamate effect in most brain regions, which may suggest better long-term tolerability
Pharmacodynamic MRS Preliminary Findings
- Potential Distinct Neurochemical Footprint: When participants took AL001, multiple brain chemicals trended downward, while the same chemicals trended upward in those same participants when they took lithium carbonate. This suggests that AL001 may interact with the brain in a distinct manner and have a less disruptive effect on healthy brain tissue than lithium carbonate.
- Trends Towards Myo-Inositol Reduction: Both AL001 and lithium carbonate reduced levels of a key brain chemical called myo-inositol - which is exactly what lithium-based treatments are supposed to do. Notably, AL001 affected this target in nearly twice as many brain regions (17 out of 18) as lithium carbonate (8 out of 18), suggesting AL001 may deliver lithium's intended benefits more broadly throughout the brain.
- Potentially Preserved Glutamate Homeostasis: Glutamate, a key chemical messenger in the brain, was largely undisturbed in 10 of the 18 brain regions of patients after two-weeks of AL001, while two-weeks of lithium carbonate seemed to have caused disruptions to glutamate levels across every brain region measured. Keeping glutamate stable is important for long-term brain health, which suggests AL001 may have fewer side effects than lithium carbonate over time, however, this needs confirmation over a longer duration of exposure.
"Lithium carbonate has been a cornerstone of psychiatric treatment for over 55 years, but its harsh side effect profile has always limited how widely and how long it can be used," said Stephan Jackman, Chief Executive Officer of Alzamend. "These findings suggest AL001 may finally change that equation, delivering what lithium does best, without much of what makes it difficult to tolerate. That is a potential game changer for 43+ Million Americans living with BD, Alzheimer's, MDD and PTSD. We are seeking to confirm these findings in larger, adequately powered studies."
Hypotheses Generated for Future Confirmatory Studies
Based on these initial findings, Alzamend has identified the following pharmacodynamic hypotheses to be tested in future confirmatory studies involving subjects with Alzheimer's, BD, MDD and PTSD:
- AL001 causes less disruption to healthy brain tissue than lithium carbonate, potentially resulting in fewer side effects and better long-term tolerability;
- AL001 produces the same beneficial brain response that makes lithium an effective treatment, by reducing a key brain chemical, myo-inositol, suggesting it works through the same proven mechanism of action as lithium carbonate, just with a potentially better safety profile;
- AL001 appears to leave glutamate levels in healthy brain tissue largely undisturbed, a potentially important advantage over lithium carbonate, which appears to disrupt glutamate broadly. Stable glutamate levels in healthy tissue may mean fewer cognitive side effects and better long-term tolerability for patients; and
- Unlike lithium carbonate, AL001 may help preserve the health of brain cell membranes in healthy tissue, the protective outer layer of brain cells that play a critical role in how they function and communicate. If confirmed, this could mean AL001 is better tolerated by patients over the long-term than lithium carbonate.
AL001: A Differentiated Lithium Therapy for a Large Unmet Need
Although lithium has remained the gold standard treatment for bipolar disorder for more than 55 years, its clinical utility is constrained by a narrow therapeutic window and the need for regular therapeutic drug monitoring to manage renal, thyroid, and other systemic toxicity risks. AL001 is Alzamend's patented ionic cocrystal formulation of lithium combined for delivery with L-proline and salicylate, which is designed to deliver a full therapeutic amount of lithium to the brain with less systemic exposure than lithium carbonate, potentially enabling a safer, better-tolerated therapy across Alzheimer's, BD, MDD and PTSD.
About this Study
Brain metabolite concentrations were assessed using ultra-high field high-resolution magnetic resonance spectroscopic imaging (MRSI) in six healthy volunteers following blood-bioequivalent and lithium-dose equivalent 14-day multiple doses of AL001 and lithium carbonate treatments in a randomized, crossover design across 18 brain regions. The five metabolites analyzed were: total creatine (Cr+PCr), glutamate (Glu), glycerophosphocholine plus phosphocholine (GPC+PCh), myo-inositol (Ins), and N-acetylaspartate plus N-acetylaspartylglutamate (NAA+NAAG). Statistical analyses used the Wilcoxon signed-rank test and Hedges' g effect-size measure, with a pre-specified ≥
About Alzamend Neuro
Alzamend is a clinical-stage biopharmaceutical company developing novel therapies for Alzheimer's, BD, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001, a patented ionic cocrystal delivering lithium with salicylate and L-proline designed to improve brain delivery and safety compared to conventional lithium, and ALZN002, a patented cell-based therapeutic vaccine designed to restore the immune system's ability to clear Alzheimer's beta-amyloid. The latter is a next-generation active-immunity approach offering potential advantages in dosing frequency and cost compared to approved passive-immunity antibody therapies. Both candidates are exclusively licensed from the University of South Florida Research Foundation under royalty-bearing worldwide licenses.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "believes," "plans," "anticipates," "projects," "estimates," "expects," "intends," "strategy," "future," "opportunity," "may," "will," "should," "could," "potential," or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and Alzamend undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect Alzamend's business and financial results are included in Alzamend's filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/alzamend-neuro-reports-encouraging-pharmacodynamic-data-from-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-in-a-trial-conducted-at-massachusetts-general-hospital-302735711.html
SOURCE Alzamend Neuro, Inc.